<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vasopressin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vasopressin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vasopressin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10039" href="/d/html/10039.html" rel="external">see "Vasopressin: Drug information"</a> and <a class="drug drug_patient" data-topicid="12150" href="/d/html/12150.html" rel="external">see "Vasopressin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9559967"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vasostrict</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1062878"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidiuretic Hormone Analog</span>;</li>
<li>
<span class="list-set-name">Hormone, Posterior Pituitary</span></li></ul></div>
<div class="block don drugH1Div" id="F53462618"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Units of measure vary by indication and age (ie, milliunits/kg/<b>hour</b>, units/kg/<b>hour</b>, milliunits/kg/minute, units/kg/minute; <b>units/minute</b>, units/<b>hour</b>); extra precautions should be taken.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ecaf0059-21dc-4460-a7ab-60df13812c6c">Cardiac surgery; post-bypass</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac surgery (complex procedure; eg, Norwood; arterial switch); post-bypass:</b> Limited data available: Continuous IV infusion: Mean reported dose range: 0.3 to 0.5 milliunits/kg/minute, titrated to hemodynamic goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21926664','lexi-content-ref-21554826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21926664','lexi-content-ref-21554826'])">Ref</a></span>). Dosing based on experience in 37 neonates (n=19 in vasopressin group) which showed a mean infusion rate: 0.3 milliunits/kg/minute (range: 0.08 to 1 milliunit/kg/minute) was associated with decreased catecholamine use and significant reduction in fluid resuscitation during first 24 hours after surgery compared to the control group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21926664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21926664'])">Ref</a></span>); a retrospective report of 28 neonates with refractory hemodynamic instability after Norwood palliation showed improvement in urine output, SBP, and pH markers with vasopressin at a mean infusion rate of 0.5 milliunits/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21554826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21554826'])">Ref</a></span>). <b>Note:</b> Hyponatremia reported frequently; monitor serum Na (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21926664','lexi-content-ref-23392370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21926664','lexi-content-ref-23392370'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47e7f7ec-44cd-4ef8-9138-779f180b0c90">Hypotension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension (initial therapy):</b> Very limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25039051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25039051'])">Ref</a></span>): ELBW neonates (GA ≤30 weeks): Continuous IV infusion: Reported range: 0.17 to 0.67 milliunits/kg/minute (0.01 to 0.04 units/kg/<b>hour</b>); dosing initiated at low end of range and titrated at 20 minute intervals in 0.17 milliunits/kg/minute (0.01 units/kg/<b>hour</b>) increments. Dosing based on a prospective, randomized, double-blind trial comparing vasopressin and dopamine as initial therapy in 20 hypotensive ELBW neonates (vasopressin treatment group, n=10; mean GA: 25.7 weeks; PNA: &lt;24 hours; mean birth weight: 640 g) with a control group of 50 normotensive ELBW neonates; primary efficacy outcomes were similar in both treatment groups; other findings showed that subjects in the vasopressin group received significantly fewer surfactant doses and had a lower mean PaCO<sub>2</sub>; and unlike the dopamine group, tachycardia was not observed in the vasopressin group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25641242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25641242'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df36279e-b5e5-489d-bf17-81a9f4d7d14d">Persistent pulmonary hypertension of the newborn, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Persistent pulmonary hypertension of the newborn (PPHN), refractory:</b> Very limited data available: GA ≥37 weeks: Continuous IV infusion: Initial: 0.1 milliunits/kg/minute, increase in 0.1 milliunits/kg/minute increments every hour as needed for clinical response to a maximum dose of 1.2 milliunits/kg/minute; dosing based on a case series in 10 neonates (GA ≥37 weeks; birth weight ≥2.2 kg) which showed significant improvement in oxygenation index, blood pressure, and urine output and a reduction in iNO dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24141655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24141655'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="902acf2e-a1f8-44e9-9e1d-6ba10d105342">Shock; vasodilatory with refractory hypotension unresponsive to fluid resuscitation and exogenous catecholamines</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shock; vasodilatory with refractory hypotension unresponsive to fluid resuscitation and exogenous catecholamines:</b> Limited data available; dosing regimens and efficacy results variable: Continuous IV infusion: 0.17 to 10 milliunits/kg/minute (0.01 to 0.6 units/kg/<b>hour</b>) have been used; doses were initiated at the lower end of the range and titrated to effect in most studies. Dosing based on retrospective reviews and case reports that have shown increases in arterial blood pressure and urine output and also allowed for dosage reductions of additional vasopressors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20727442','lexi-content-ref-19325359','lexi-content-ref-18496412','lexi-content-ref-19793209','lexi-content-ref-18081903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20727442','lexi-content-ref-19325359','lexi-content-ref-18496412','lexi-content-ref-19793209','lexi-content-ref-18081903'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F233612"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Units of measure vary by indication and age (ie, milliunits/kg/<b>hour</b>, units/kg/<b>hour</b>, milliunits/kg/minute, units/kg/minute; <b>units/minute</b>, units/<b>hour</b>); extra precautions should be taken.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ef5f419-b63a-4776-a041-6dfb545e5ac2">Diabetes insipidus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes insipidus: Note:</b> Highly variable dosage; titrate dosage based upon serum and urine sodium and osmolality in addition to fluid balance and urine output. Children and Adolescents: IM, SubQ: 2.5 to 10 units 2 to 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Central diabetes insipidus:</i> Limited data available: Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.5 milliunits/kg/<b>hour</b>; titrate upward in 0.5 milliunits/kg/<b>hour</b> increments at approximately 10-minute intervals to target urine output (suggested output target: &lt;2 mL/kg/hour) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sperling.1','lexi-content-ref-15211159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sperling.1','lexi-content-ref-15211159'])">Ref</a></span>); infusion rates up to 10 milliunits/kg/<b>hour</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23314181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23314181'])">Ref</a></span>). <b>Note:</b> Use in conjunction with fluid therapy, monitor urine output and specific gravity, serum and urine electrolytes (primarily Na), and plasma osmolality.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75b797a8-f164-47ba-843f-afb034aa69bd">Cadaveric organ donations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cadaveric organ donations (hormone replacement therapy):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nakagawa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nakagawa.1'])">Ref</a></span>): Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.5 to 1 milliunits/kg/<b>hour</b>; titrate dose to maintain targeted urine output. In a retrospective case-controlled study (n=34, age: 8.2 ± 6.2 years), a mean dose of 41 milliunits/kg/<b>hour</b> was reported with a range of 0.2 milliunits/kg/<b>hour</b> to 150 milliunits/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11004379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11004379'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6130374-00f9-4920-a731-21fc4ed00afc">GI hemorrhage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>GI hemorrhage:</b> Limited data available: Children and Adolescents: Continuous IV infusion: Initial: 2 to 5 milliunits/kg/minute; titrate dose as needed; maximum dose: 10 milliunits/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007','lexi-content-ref-3144593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007','lexi-content-ref-3144593'])">Ref</a></span>); usual adult dosing range is 0.2 to 0.4 <b>units/minute</b> up to a maximum rate of 0.8 <b>units/minute</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17879356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17879356'])">Ref</a></span>). <b>Note:</b> Higher doses have not been associated with greater efficacy but have been associated with increased risk of complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3144593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3144593'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="648a1813-e099-4936-b0b9-ad5ab446a9f4">Pulseless arrest, ventricular fibrillation, ventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulseless arrest, ventricular fibrillation, ventricular tachycardia:</b> Limited data available: Infants, Children, and Adolescents: IV: 0.4 units/kg as a single dose after traditional resuscitation methods and at least two doses of epinephrine have been administered. <b>Note:</b> Due to insufficient evidence, no formal recommendations for or against the routine use of vasopressin during pediatric cardiac arrest are provided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19188873','lexi-content-ref-11841882','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19188873','lexi-content-ref-11841882','lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="584285b3-978e-49a6-a87e-00203e49af18">Vasodilatory shock with hypotension unresponsive to fluid resuscitation and exogenous catecholamines</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasodilatory shock with hypotension unresponsive to fluid resuscitation and exogenous catecholamines:</b> Limited data available; efficacy results have varied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23353941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23353941'])">Ref</a></span>): Infants, Children, and Adolescents: Continuous IV infusion: 0.17 to 8 milliunits/kg/minute (0.01 to 0.48 units/kg/<b>hour</b>) has been used; dosing based on retrospective reviews and case reports that have shown increases in arterial blood pressure and urine output and also allowed for dosage reductions of additional vasopressors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19325359','lexi-content-ref-18496412','lexi-content-ref-18081903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19325359','lexi-content-ref-18496412','lexi-content-ref-18081903'])">Ref</a></span>). The only double-blind, placebo-controlled trial (n=65, age: 3 to 14 years) evaluated a dose of 0.5 to 2 milliunits/kg/minute (0.03 to 0.12 units/kg/<b>hour</b>) at multiple centers and found no significant difference in the time to reach hemodynamic stability and a trend toward increased mortality in the vasopressin group was noted. Based on these findings, the authors did not recommend routine use of vasopressin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19608718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19608718'])">Ref</a></span>). <b>Note:</b> Abrupt discontinuation of infusion may result in hypotension; to discontinue, gradually taper infusion.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193248"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193249"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F233598"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10039" href="/d/html/10039.html" rel="external">see "Vasopressin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81f8f7e2-12a2-41ce-9684-a0869ba7fcf2">Cadaveric organ recovery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cadaveric organ recovery (hormone replacement therapy) (off-label use):</b> Based on limited data: <b>Note:</b> Use if hypotensive despite adequate fluid resuscitation, left ventricular ejection fraction &lt;45%, low systemic vascular resistance (SVR), or if diabetes insipidus is present. Use in combination with levothyroxine (or liothyronine), methylprednisolone, and continuous insulin infusion (goal blood glucose: 120 to 180 mg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25978154','lexi-content-ref-12176957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25978154','lexi-content-ref-12176957'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 0.01 to 0.04 units/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25978154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25978154'])">Ref</a></span>); some experts recommend a bolus of 1 unit followed by 0.01 to 0.1 units/minute titrated to a SVR of 800 to 1,200 dyne•second/cm<sup>5</sup> (usual dose: 0.01 to 0.04 units/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Garrity.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Garrity.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0abb4c4d-97b2-469f-9d23-5b67a088f30b">Diabetes insipidus, central</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes insipidus, central (acute) (off-label use): Note:</b> Dosage is highly variable; titrated based on serum and urine sodium and osmolality in addition to fluid balance and urine output. Vasopressin may be considered for short-term use in some neurocritical care settings due to its short duration of action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27736313','lexi-content-ref-21507850','lexi-content-ref-28377801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27736313','lexi-content-ref-21507850','lexi-content-ref-28377801'])">Ref</a></span>). Use in neurosurgical patients is generally limited to the early postoperative period (eg, days 1 to 4); use caution in this setting to avoid overtreatment, as diabetes insipidus may spontaneously resolve or revert to syndrome of inappropriate antidiuretic hormone secretion/hyponatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27736313','lexi-content-ref-28377801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27736313','lexi-content-ref-28377801'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ</b> (off-label route): 5 to 10 units 2 to 3 times daily as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377801'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion:<b> IV:</b> Continuous infusion has not been formally evaluated in the post-neurosurgical adult. However, some clinicians may convert SUBQ requirement to an hourly continuous IV infusion rate with careful titration based on urine output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21507850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21507850'])">Ref</a></span>). Specific protocols may vary.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6c74a844-40e6-4022-873b-e374368adece">Gastroesophageal variceal hemorrhage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal variceal hemorrhage (alternative agent) (off-label use): Note:</b> Other therapies (eg, octreotide) may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17879356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17879356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: <b>IV: </b>Initial: 0.2 to 0.4 units/minute, may titrate dose as needed to a maximum dose of 0.8 units/minute; maximum duration is 24 hours at highest effective dose (to reduce incidence of adverse effects). Administer IV nitroglycerin concurrently to prevent ischemic complications; monitor closely for signs/symptoms of ischemia (myocardial, peripheral, bowel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17879356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17879356'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="25b97a8f-8e14-4a06-b25d-78c7f5328beb">Septic shock and other vasodilatory shock states</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic shock and other vasodilatory shock states (adjunctive agent): </b>
<b>Note:</b> Considered as adjunctive use when goal mean arterial pressure (MAP) not achieved with initial catecholamine vasopressor (eg, norepinephrine) or to decrease catecholamine vasopressor dosage requirements. In general, maintain goal MAP (eg, ~65 mm Hg); consider use if patient is in shock or has hypoperfusion during or after fluid resuscitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23353941','lexi-content-ref-34605781','lexi-content-ref-29767636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23353941','lexi-content-ref-34605781','lexi-content-ref-29767636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Shock, sepsis: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion: <b>IV: </b>0.03 units/minute added to norepinephrine as a fixed dose (not titrated); usual dosage range: 0.01 to 0.04 units/minute; doses &gt;0.04 units/minute should be reserved for salvage therapy due to potential risk of ischemic complications (eg, skin, cardiac, splanchnic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251906','lexi-content-ref-12771608','lexi-content-ref-14605537','lexi-content-ref-18305265','lexi-content-ref-32820475','lexi-content-ref-23353941','lexi-content-ref-28101605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251906','lexi-content-ref-12771608','lexi-content-ref-14605537','lexi-content-ref-18305265','lexi-content-ref-32820475','lexi-content-ref-23353941','lexi-content-ref-28101605'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Discontinuation in septic shock: </i>Multiple studies describe clinically significant hypotension when vasopressin is discontinued prior to norepinephrine. When discontinuing therapy, consider slowly tapering by 0.01 units/minute every 30 to 60 minutes to reduce the risk of hypotension; monitor MAP when discontinuing vasopressin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19926252','lexi-content-ref-28750598','lexi-content-ref-29784057','lexi-content-ref-Manaker.1','lexi-content-ref-29560736','lexi-content-ref-29328496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19926252','lexi-content-ref-28750598','lexi-content-ref-29784057','lexi-content-ref-Manaker.1','lexi-content-ref-29560736','lexi-content-ref-29328496'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Shock, post-cardiotomy:</i></b> Continuous infusion: <b>IV:</b> Initial: 0.03 units/minute. If the target blood pressure response is not achieved, titrate up by 0.005 units/minute at 10- to 15-minute intervals (maximum dose: 0.1 units/minute). After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper by 0.005 units/minute every hour as tolerated to maintain target blood pressure.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992084"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989285"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F233560"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, bradycardia, ischemic heart disease, limb ischemia (distal), low cardiac output, right heart failure, shock (hemorrhagic)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin lesion (ischemic)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Mesenteric ischemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased platelet count, hemorrhage (intractable)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Endocrine &amp; metabolic: Diabetes insipidus (reversible)</p></div>
<div class="block coi drugH1Div" id="F233577"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to vasopressin or any component of the formulation; hypersensitivity to chlorobutanol (Vasostrict 10 mL vial only).</p></div>
<div class="block war drugH1Div" id="F233557"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes insipidus: Reversible diabetes insipidus may occur following discontinuation of vasopressin therapy; signs/symptoms may include polyuria, dilute urine, and hypernatremia. Monitor electrolytes, fluid status, and urine output after vasopressin discontinuation. Readministration of vasopressin (or desmopressin) may be needed to correct fluid and electrolyte imbalances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Extravasation may lead to severe vasoconstriction and localized tissue necrosis; also, gangrene of extremities, tongue, and ischemic colitis. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Water intoxication: May cause water intoxication; early signs include drowsiness, listlessness, and headache; these should be recognized to prevent coma and seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including arteriosclerosis; may worsen cardiac output.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use with caution in patients with a history of migraines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vascular disease: Use with caution in patients with vascular disease.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878667"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May cause hyponatremia; frequency not well-defined in pediatric patients and may vary based on indication. In young pediatric patients (mean age: 5.2 months; including neonates) who received a vasopressin infusion for hemodynamic instability following complex cardiac surgery, the observed incidence of hyponatremia (defined as serum Na &lt;135 mEq/L) was statistically higher in the vasopressin group than the control (48% vs 17%, p=0.004) and the decrease in serum sodium concentration was significantly greater (9.9 mEq/L vs 7.5 mEq/L, p=0.009); it was also observed that the decrease in the serum Na was more rapid in the vasopressin group (Davalos 2013). With other uses in pediatric patients, hyponatremia has not been characterized; monitor fluid balance, serum Na and urine output closely.</p></div>
<div class="block foc drugH1Div" id="F233569"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vasostrict: 0.2 units/mL (100 mL); 0.4 units/mL (100 mL); 20 units/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vasostrict: 20 units/mL (10 mL) [contains chlorobutanol (chlorobutol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 units/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 units/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F233553"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324084"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vasopressin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 units/mL (per mL): $27.60 - $189.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vasostrict Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 units/mL (per mL): $2.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 units/mL (per mL): $5.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 units/mL (per mL): $97.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868582"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 units/mL (1 mL, 2 mL, 5 mL)</p></div>
<div class="block admp drugH1Div" id="F52614002"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">IM, SubQ: Administer without further dilution. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Continuous IV infusion: Dilute prior to administration. Infusion through central line is strongly recommended.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative antidote) (see Management of Drug Extravasations for more details).</p></div>
<div class="block adm drugH1Div" id="F233574"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ</b> (off-label route): Administer without further dilution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Continuous IV infusion:</b> Dilute 1 mL and 10 mL vials prior to administration; premixed vials (20 units/100 mL and 40 units/100 mL) requiring no further dilution are also available for single use. Infusion through central line is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry, warm compresses. Initiate topical nitroglycerin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141794','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141794','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nitroglycerin (topical): </i>Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover the affected area; may repeat every 8 hours as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Alternatives to nitroglycerin </i>
<i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141794'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Phentolamine:</i>
<b>SUBQ: </b>Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose IV through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Terbutaline:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Large extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Small extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with terbutaline 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F233588"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials between 2°C and 8°C (36°F and 46°F). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">May also remove intact vials from refrigeration and store at 20°C to 25°C (68°F to 77°F) for up to 12 months or manufacturer expiration date, whichever is earlier (indicate date of removal on the vial or note the manufacturer expiration date, whichever is earlier). After initial entry into the 10 mL vial, opened vial must be refrigerated; discard 30 days after first puncture. Discard unused diluted solution (in D5W or NS) after 18 hours at room temperature or 24 hours under refrigeration.</p></div>
<div class="block usep drugH1Div" id="F53569432"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Pitressin (synthetic): Treatment of diabetes insipidus (FDA approved in pediatric patients [age not specified] and adults) </p>
<p style="text-indent:-2em;margin-left:2em;">Vasostrict: To increase blood pressure in patients with vasodilatory shock (eg, postcardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used as an adjunct in the treatment of acute massive GI hemorrhage; treatment of pulseless arrest, ventricular fibrillation or tachycardia, and asystole/pulseless electrical activity; systemic hypotension and persistent pulmonary hypertension in neonates; and cadaveric organ donation </p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although abdominal roentgenography and postoperative abdominal distention (prevention/treatment) are included as FDA approved uses in the manufacturer's prescribing information, there is insufficient evidence to recommend the use of vasopressin for these indications. A data review determined that the evidence was insufficient to recommend the use of vasopressin in the setting of postoperative adynamic ileus following abdominal surgery (Traut 2008). Vasopressin has been removed from the adult cardiac arrest algorithm; based on the 2015 American Heart Association (AHA) Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, vasopressin offers no advantage as a substitute for epinephrine and no advantage when used in combination with epinephrine as a substitute for standard dose epinephrine in adult cardiac arrest (ventricular fibrillation [VF]/pulseless ventricular tachycardia [pVT], asystole, or pulseless electrical activity [PEA]). </p></div>
<div class="block mst drugH1Div" id="F9517809"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PIT or Pitressin (old names sometimes used to describe vasopressin) may be confused with Pitocin</p>
<p style="text-indent:-2em;margin-left:4em;">Vasopressin may be confused with desmopressin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV or intraosseous administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Use care when prescribing and/or administering vasopressin solutions. Close attention should be given to concentration of solution, route of administration, dose, and rate of administration (units/minute, units/kg/minute, units/kg/hour).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300210"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F233562"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Direct-Acting): May enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drugs Suspected of Causing Diabetes Insipidus: May diminish the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic hormone effects of vasopressin may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drugs Suspected of Causing SIADH: May enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indomethacin: May enhance the therapeutic effect of Vasopressin. Specifically, vasopressin effects on cardiac index and systemic vascular resistance may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: May enhance the therapeutic effect of Vasopressin. Specifically, the effect of vasopressin on mean arterial blood pressure may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F233580"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Vasopressin may produce tonic uterine contractions. Due to pregnancy-induced physiologic changes, vasopressin clearance may be increased in the second and third trimesters; dose adjustment may be needed. Clearance returns to normal within 2 weeks postpartum.</p></div>
<div class="block mopp drugH1Div" id="F53569431"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Specific monitoring determined by indication and may include: Blood pressure, heart rate, fluid intake and output, urine specific gravity, urine and serum osmolality; serum and urine sodium: Hemoglobin and hematocrit (GI bleeding). Consult individual institutional policies and procedures.</p></div>
<div class="block rerp drugH1Div" id="F53568999"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Vasopressin concentration:</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Basal: &lt;4 pg/mL</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Water deprivation: 10 pg/mL</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Shock: 100 to 1,000 pg/mL (biphasic response)</p></div>
<div class="block pha drugH1Div" id="F233556"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vasopressin stimulates a family of arginine vasopressin (AVP) receptors, oxytocin receptors, and purinergic receptors (Russell 2011). Vasopressin, at therapeutic doses used for vasodilatory shock, stimulates the AVPR1a (or V1) receptor and increases systemic vascular resistance and mean arterial blood pressure; in response to these effects, a decrease in heart rate and cardiac output may be seen. When the AVPR2 (or V2) receptor is stimulated, cyclic adenosine monophosphate (cAMP) increases which in turn increases water permeability at the renal tubule resulting in decreased urine volume and increased osmolality. Vasopressin, at pressor doses, also causes smooth muscle contraction in the GI tract by stimulating muscular V1 receptors and release of prolactin and ACTH via AVPR1b (or V3) receptors.</p></div>
<div class="block phk drugH1Div" id="F233576"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Antidiuretic: Peak effect: 1 to 2 hours (Murphy-Human 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Vasopressor effect: IV: Rapid with peak effect occurring within 15 minutes of initiation of continuous IV infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: SUBQ: Antidiuretic: 2 to 8 hours; IV: Vasopressor effect: Within 20 minutes after IV infusion terminated.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: None from GI tract, destroyed by trypsin in GI tract, must be administered parenterally.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 140 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: None.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, renal (inactive metabolites).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV, SubQ: 10 to 20 minutes (apparent half-life: ≤10 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: SUBQ: Urine (5% as unchanged drug) after 4 hours; IV: Urine (~6% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038856"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Pitressin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Vasopresina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Pitressin | Vascel</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Pitressin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Pitressin | Pitressin tannate oil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Pitressin Tannate</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pitressin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pitressin | Vasostrict</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Embesin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Pitressin Tannate</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Pitressin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23314181">
<a name="23314181"></a>Alharfi IM, Stewart TC, Foster J, Morrison GC, Fraser DD. Central diabetes insipidus in pediatric severe traumatic brain injury. <i>Pediatr Crit Care Med</i>. 2013;14(2):203-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/23314181/pubmed" id="23314181" target="_blank">23314181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ali.1">
<a name="Ali.1"></a>Ali KF, San Martin VT, El-Hage L, et al. A newly devised vasopressin drip protocol in the management of chronic central diabetes insipidus during facial transplantation surgery. <i>AACE Clin Case Rep</i>. 2018;4(6):e497-e500.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21926664">
<a name="21926664"></a>Alten JA, Borasino S, Toms R, Law MA, Moellinger A, Dabal RJ. Early initiation of arginine vasopressin infusion in neonates after complex cardiac surgery. <i>Pediatr Crit Care Med</i>. 2012;13(3):300-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/21926664/pubmed" id="21926664" target="_blank">21926664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19926252">
<a name="19926252"></a>Bauer SR, Aloi JJ, Ahrens CL, Yeh JY, Culver DA, Reddy AJ. Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: a retrospective cohort study. <i>J Crit Care</i>. 2010;25(2):362.e7-362.e11. doi:10.1016/j.jcrc.2009.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19926252/pubmed" id="19926252" target="_blank">19926252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251906">
<a name="33251906"></a>Bauer SR, Sacha GL, Lam SW, et al. Hemodynamic response to vasopressin dosage of 0.03 units/min vs. 0.04 units/min in patients with septic shock. <i>J Intensive Care Med</i>. 2020:885066620977181. doi:10.1177/0885066620977181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/33251906/pubmed" id="33251906" target="_blank">33251906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20727442">
<a name="20727442"></a>Bidegain M, Greenberg R, Simmons C, et al, "Vasopressin for Refractory Hypotension in Extremely Low Birth Weight Infants," <i>J Pediatr</i>, 2010, 157(3):502-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/20727442/pubmed" id="20727442" target="_blank">20727442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28750598">
<a name="28750598"></a>Bissell BD, Magee C, Moran P, Bastin MLT, Flannery AH. Hemodynamic instability secondary to vasopressin withdrawal in septic shock. <i>J Intensive Care Med</i>. 2019;34(9):761-765. doi:10.1177/0885066617716396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/28750598/pubmed" id="28750598" target="_blank">28750598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325359">
<a name="19325359"></a>Brierley J, Carcillo JA, Choong K. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009;37(2):666-688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19325359/pubmed" id="19325359" target="_blank">19325359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21554826">
<a name="21554826"></a>Burton GL, Kaufman J, Goot BH, da Cruz EM. The use of arginine vasopressin in neonates following the Norwood procedure. <i>Cardiol Young</i>. 2011;21(5):536-544.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/21554826/pubmed" id="21554826" target="_blank">21554826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24176209">
<a name="24176209"></a>Callahan DS, Neville A, Bricker S, et al. The effect of arginine vasopressin on organ donor procurement and lung function. <i>J Surg Res</i>. 2014;186(1):452-457. doi:10.1016/j.jss.2013.09.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/24176209/pubmed" id="24176209" target="_blank">24176209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-313353">
<a name="313353"></a>Chojkier M, Groszmann RJ, Atterbury CE, et al. A Controlled Comparison of Continuous Intraarterial and Intravenous Infusions of Vasopressin in Hemorrhage From Esophageal Varices. <i>Gastroenterology</i>. 1979;77(3):540-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/313353/pubmed" id="313353" target="_blank">313353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18496412">
<a name="18496412"></a>Choong K and Kissoon N. Vasopressin in pediatric shock and cardiac arrest. <i>Pediatr Crit Care Med.</i> 2008;9(4):372-379. doi:10.1097/PCC.0b013e318172d7c8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/18496412/pubmed" id="18496412" target="_blank">18496412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19608718">
<a name="19608718"></a>Choong K, Bohn D, Fraser DD, et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. <i>Am J Respir Crit Care Med.</i> 2009;180(7):632-639. doi:10.1164/rccm.200902-0221OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19608718/pubmed" id="19608718" target="_blank">19608718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23392370">
<a name="23392370"></a>Davalos MC, Barrett R, Seshadri S, et al. Hyponatremia during arginine vasopressin therapy in children following cardiac surgery. <i>Pediatr Crit Care Med</i>. 2013;14(3):290-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/23392370/pubmed" id="23392370" target="_blank">23392370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637. doi:10.1097/CCM.0b013e31827e83af<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2510208">
<a name="2510208"></a>Denkler KA, Cohen BE. Reversal of dopamine extravasation injury with topical nitroglycerin ointment. <i>Plast Reconstr Surg</i>. 1989;84(5):811-813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/2510208/pubmed" id="2510208" target="_blank">2510208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188873">
<a name="19188873"></a>Duncan JM, Meaney P, Simpson P, et al. Vasopressin for in-hospital pediatric cardiac arrest: results from the American Heart Association National Registry of Cardiopulmonary Resuscitation. <i>Pediatr Crit Care Med.</i> 2009;10(2):191-955. doi:10.1097/PCC.0b013e31819a36f2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19188873/pubmed" id="19188873" target="_blank">19188873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771608">
<a name="12771608"></a>Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. <i>Crit Care Med</i>. 2003;31(5):1394-1398. doi:10.1097/01.CCM.0000059722.94182.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/12771608/pubmed" id="12771608" target="_blank">12771608</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dunser MW, Mayr AJ, Ulmer H, et al, “The Effects of Vasopressin on Systemic Hemodynamics in Catecholamine-Resistant Septic and Postcardiotomy Shock: A Retrospective Analysis,” <i>Anest Analg</i>, 2001, 93(1):7-13.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med.</i> 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736313">
<a name="27736313"></a>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888-3921. doi: 10.1210/jc.2016-2118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/27736313/pubmed" id="27736313" target="_blank">27736313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17879356">
<a name="17879356"></a>Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis [published correction appears in <i>Hepatology</i>. 2007;46(6):2052]. <i>Hepatology</i>. 2007;46(3):922-938.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/17879356/pubmed" id="17879356" target="_blank">17879356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27786365">
<a name="27786365"></a>Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2017;65(1):310-335. doi:10.1002/hep.28906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/27786365/pubmed" id="27786365" target="_blank">27786365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Garrity.1">
<a name="Garrity.1"></a>Garrity ER, Bag R, O'Connor MF, Dalton A. Management of the deceased organ donor. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/use-of-vasopressors-and-inotropes?search=Use%20of%20vasopressors%20and%20inotropes&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed February 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11373445">
<a name="11373445"></a>Gazmuri RJ and Shakeri SA, “Low-Dose Vasopressin for Reversing Vasodilation During Septic Shock,” <i>Crit Care Med</i>, 2001, 29(3):673-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/11373445/pubmed" id="11373445" target="_blank">11373445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17667395">
<a name="17667395"></a>Hadaway L, "Infiltration and Extravasation," <i>Am J Nurs</i>, 2007, 107(8):64-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/17667395/pubmed" id="17667395" target="_blank">17667395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28618919">
<a name="28618919"></a>Hammond DA, McCain K, Painter JT, et al. Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock [published online ahead of print January 1, 2017]. <i>J Intensive Care Med</i>. doi: 10.1177/0885066617714209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/28618919/pubmed" id="28618919" target="_blank">28618919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hodges.1">
<a name="Hodges.1"></a>Hodges BM and Fraser G, "Vasopressin for Vasodilatory Shock," <i>Hosp Pharm</i>, 2002, 37(11):1149-57.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15343024">
<a name="15343024"></a>Hollenberg SM, Ahrens TS, Annane D, et al, “Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,” <i>Crit Care Med</i>, 2004, 32(9):1928-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/15343024/pubmed" id="15343024" target="_blank">15343024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holmes.1">
<a name="Holmes.1"></a>Holmes CL, Walley KR, Chittock DR, et al, “The Effects of Vasopressin on Hemodynamics and Renal Function in Severe Septic Shock: A Case Series,” <i>Inten Care Med</i>, 2001, 27(8):1416-21.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19793209">
<a name="19793209"></a>Ikegami H, Funato M, Tamai H, et al, "Low-Dose Vasopressin Infusion Therapy for Refractory Hypotension in ELBW Infants," <i>Pediatr Int</i>, 2010, 52(3):368-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19793209/pubmed" id="19793209" target="_blank">19793209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29784057">
<a name="29784057"></a>Jeon K, Song JU, Chung CR, Yang JH, Suh GY. Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS). <i>Crit Care</i>. 2018;22(1):131. doi:10.1186/s13054-018-2034-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/29784057/pubmed" id="29784057" target="_blank">29784057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12163813">
<a name="12163813"></a>Kahn JM, Kress JP, Hall JB. Skin Necrosis After Extravasation of Low-Dose Vasopressin Administered for Septic Shock. <i>Crit Care Med</i>. 2002;30(8):1899-1901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/12163813/pubmed" id="12163813" target="_blank">12163813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11004379">
<a name="11004379"></a>Katz K, Lawler J, Wax J, et al. Vasopressin Pressor Effects in Critically Ill Children During Evaluation for Brain Death and Organ Recovery. <i>Resuscitation</i>. 2000;47(1):33-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/11004379/pubmed" id="11004379" target="_blank">11004379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15178897">
<a name="15178897"></a>Kill C, Wranze E, Wulf H. Successful Treatment of Severe Anaphylactic Shock With Vasopressin. <i>Int Arch Allergy Immunol</i>. 2004;134(3):260-261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/15178897/pubmed" id="15178897" target="_blank">15178897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation. </i>2010;122(18)(suppl 3):S876-S908. doi:10.1161/CIRCULATIONAHA.110.971101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14605537">
<a name="14605537"></a>Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. <i>Crit Care Med</i>. 2003;31(11):2646-2650. doi:10.1097/01.CCM.0000094260.05266.F4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/14605537/pubmed" id="14605537" target="_blank">14605537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16118265">
<a name="16118265"></a>Koshman SL, Zed PJ, Abu-Laban RB. Vasopressin in Cardiac Arrest. <i>Ann Pharmacother</i>. 2005;39(10):1687-1692.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/16118265/pubmed" id="16118265" target="_blank">16118265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25978154">
<a name="25978154"></a>Kotloff RM, Blosser S, Fulda GJ, et al; Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Donor Management Task Force. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations consensus statement. <i>Crit Care Med</i>. 2015;43(6):1291-1325. doi:10.1097/CCM.0000000000000958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/25978154/pubmed" id="25978154" target="_blank">25978154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15098812">
<a name="15098812"></a>Kristeller JL, Sterns RH. Transient diabetes insipidus after discontinuation of therapeutic vasopressin. <i>Pharmacotherapy</i>. 2004;24(4):541-545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/15098812/pubmed" id="15098812" target="_blank">15098812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9054839">
<a name="9054839"></a>Landry DW, Levin HR, Gallant EM, et al. Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock. <i>Circulation</i>. 1997;95(5):1122-1125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/9054839/pubmed" id="9054839" target="_blank">9054839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9267938">
<a name="9267938"></a>Landry DW, Levin HR, Gallant EM, et al. Vasopressin Pressor Hypersensitivity in Vasodilatory Septic Shock. <i>Crit Care Med</i>. 1997;25(8):1279-1282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/9267938/pubmed" id="9267938" target="_blank">9267938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6737531">
<a name="6737531"></a>Levitt MA, Fleischer AS, Meislin HW. Acute Post-traumatic Diabetes Insipidus: Treatment with Continuous Intravenous Vasopressin. <i>J Trauma</i>. 1984;24(6):532-535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/6737531/pubmed" id="6737531" target="_blank">6737531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767636">
<a name="29767636"></a>Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. <i>Crit Care Med</i>. 2018;46(6):997-1000. doi:10.1097/CCM.0000000000003119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/29767636/pubmed" id="29767636" target="_blank">29767636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Liedel.1">
<a name="Liedel.1"></a>Liedel JL, et al. The Successful Use of Vasopressin in Children With Hypotension. <i>Crit Care Med</i>. 2001;29(12):A63.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5912596">
<a name="5912596"></a>Lindeman RD, Lee TD Jr, Yiengst MJ, et al. Influence of Age, Renal Disease, Hypertension, Diuretics, and Calcium on the Antidiuretic Responses to Suboptimal Infusions of Vasopressin. <i>J Lab Clin Med</i>. 1966;68(2):206-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/5912596/pubmed" id="5912596" target="_blank">5912596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10528604">
<a name="10528604"></a>Malay MB, Ashton RC, Landry DW, et al. Low-Dose Vasopressin in the Treatment of Vasodilatory Septic Shock.<i> J Trauma</i>. 1999;47(4):699-705.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/10528604/pubmed" id="10528604" target="_blank">10528604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manaker.1">
<a name="Manaker.1"></a>Manaker S. Use of vasopressors and inotropes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/use-of-vasopressors-and-inotropes?search=Use%20of%20vasopressors%20and%20inotropes&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed November 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11841882">
<a name="11841882"></a>Mann K, Berg RA, and Nadkarni V. Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: a case series. <i>Resuscitation.</i> 2002;52(2):149-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/11841882/pubmed" id="11841882" target="_blank">11841882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23860985">
<a name="23860985"></a>Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. <i>JAMA</i>. 2013;310(3):270-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/23860985/pubmed" id="23860985" target="_blank">23860985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19139319">
<a name="19139319"></a>Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. <i>Arch Intern Med</i>. 2009;169(1):15-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19139319/pubmed" id="19139319" target="_blank">19139319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18081903">
<a name="18081903"></a>Meyer S, Gortner L, McGuire W, et al. Vasopressin in catecholamine-refractory shock in children. <i>Anaesthesia.</i> 2008;63(3):228-234. doi:10.1111/j.1365-2044.2007.05317.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/18081903/pubmed" id="18081903" target="_blank">18081903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13130853">
<a name="13130853"></a>Miller JH, Shock NW. Age Differences in the Renal Tubular Response to Antidiuretic Hormone. <i>J Gerontol</i>. 1953;8(4):446-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/13130853/pubmed" id="13130853" target="_blank">13130853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24141655">
<a name="24141655"></a>Mohamed A, Nasef N, Shah V, McNamara PJ. Vasopressin as a rescue therapy for refractory pulmonary hypertension in neonates: case series. <i>Pediatr Crit Care Med</i>. 2014;15(2):148-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/24141655/pubmed" id="24141655" target="_blank">24141655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21507850">
<a name="21507850"></a>Murphy-Human T, Diringer MN. Sodium disturbances commonly encountered in the neurologic intensive care unit. <i>J Pharm Pract</i>. 2010;23(5):470-482. doi:10.1177/0897190010372323<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/21507850/pubmed" id="21507850" target="_blank">21507850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29560736">
<a name="29560736"></a>Musallam N, Altshuler D, Merchan C, Zakhary B, Aberle C, Papadopoulos J. Evaluating vasopressor discontinuation strategies in patients with septic shock on concomitant norepinephrine and vasopressin infusions. <i>Ann Pharmacother</i>. 2018;52(8):733-739. doi:10.1177/1060028018765187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/29560736/pubmed" id="29560736" target="_blank">29560736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nakagawa.1">
<a name="Nakagawa.1"></a>Nakagawa TA. Pediatric Donor Management Guidelines. NATCO, The Organization for Transplant Professionals. 2008. <i>UpToDate®</i>. Basow DS, ed. Waltham, MA: <i>UpToDate</i>®; 2011. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472989">
<a name="26472989"></a>Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015;132(18)(suppl 2):S315-S367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/26472989/pubmed" id="26472989" target="_blank">26472989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141794">
<a name="33141794"></a>Ong J, Van Gerpen R. Recommendations for management of noncytotoxic vesicant extravasations. <i>J Infus Nurs</i>. 2020;43(6):319-343. doi:10.1097/NAN.0000000000000392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/33141794/pubmed" id="33141794" target="_blank">33141794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23116641">
<a name="23116641"></a>Plurad DS, Bricker S, Neville A, Bongard F, Putnam B. Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. <i>Am J Surg</i>. 2012;204(6):856-860; discussion 860-861. doi:10.1016/j.amjsurg.2012.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/23116641/pubmed" id="23116641" target="_blank">23116641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28377801">
<a name="28377801"></a>Prete A, Corsello SM, Salvatori R. Current best practice in the management of patients after pituitary surgery. <i>Ther Adv Endocrinol Metab</i>. 2017;8(3):33-48. doi:10.1177/2042018816687240<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/28377801/pubmed" id="28377801" target="_blank">28377801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28895166">
<a name="28895166"></a>Rana H, Ferguson N, Dicpinigaitis PV. Diabetes insipidus after discontinuation of vasopressin infusion for septic shock. <i>J Clin Pharm Ther</i>. 2018;43(2):287-290. doi:10.1111/jcpt.12627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/28895166/pubmed" id="28895166" target="_blank">28895166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9054835">
<a name="9054835"></a>Reid IA. Role of Vasopressin Deficiency in the Vasodilation of Septic Shock. <i>Circulation</i>. 1997;95(5):1108-1110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/9054835/pubmed" id="9054835" target="_blank">9054835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25641242">
<a name="25641242"></a>Rios DR, Kaiser JR. Vasopressin versus dopamine for treatment of hypotension in extremely low birth weight infants: a randomized, blinded pilot study. <i>J Pediatr</i>. 2015;166(4):850-855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/25641242/pubmed" id="25641242" target="_blank">25641242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25039051">
<a name="25039051"></a>Rios DR, Moffett BS, Kaiser JR. Trends in pharmacotherapy for neonatal hypotension. <i>J Pediatr</i>. 2014;165(4):697-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/25039051/pubmed" id="25039051" target="_blank">25039051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12605114">
<a name="12605114"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive Pharmacologic Donor Management Results in More Transplanted Organs. <i>Transplantation</i>. 2003a;75(4):482-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/12605114/pubmed" id="12605114" target="_blank">12605114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12717226">
<a name="12717226"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. <i>Transplantation</i>. 2003b;75(8):1336-1341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/12717226/pubmed" id="12717226" target="_blank">12717226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243491">
<a name="12243491"></a>Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. <i>Am J Transplant</i>. 2002;2(8):701-711.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/12243491/pubmed" id="12243491" target="_blank">12243491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10567301">
<a name="10567301"></a>Rosenzweig EB, Starc TJ, Chen JM, et al, "Intravenous Arginine-Vasopressin in Children With Vasodilatory Shock After Cardiac Surgery," <i>Circulation</i>, 1999, 100(19 )(suppl):II182-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/10567301/pubmed" id="10567301" target="_blank">10567301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10676834">
<a name="10676834"></a>Rozenfeld V, Cheng JW. The Role of Vasopressin in the Treatment of Vasodilation in Shock States. <i>Ann Pharmacother</i>. 2000;34(2):250-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/10676834/pubmed" id="10676834" target="_blank">10676834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21892977">
<a name="21892977"></a>Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. <i>Crit Care</i>. 2011;15(4):226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/21892977/pubmed" id="21892977" target="_blank">21892977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18305265">
<a name="18305265"></a>Russell JA, Walley KR, Singer J, et al; VASST Investigators. VVasopressin versus norepinephrine infusion in patients with septic shock. <i>N Engl J Med</i>. 2008;358(9):877-887. doi:10.1056/NEJMoa067373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/18305265/pubmed" id="18305265" target="_blank">18305265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32820475">
<a name="32820475"></a>Russell JA, Gordon AC, Williams MD, Boyd JH, Walley KR, Kissoon N. Vasopressor therapy in the intensive care unit. <i>Semin Respir Crit Care Med</i>. 2021;42(1):59-77. doi:10.1055/s-0040-1710320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/32820475/pubmed" id="32820475" target="_blank">32820475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29328496">
<a name="29328496"></a>Sacha GL, Lam SW, Duggal A, Torbic H, Reddy AJ, Bauer SR. Hypotension risk based on vasoactive agent discontinuation order in patients in the recovery phase of septic shock. <i>Pharmacotherapy</i>. 2018;38(3):319-326. doi:10.1002/phar.2082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/29328496/pubmed" id="29328496" target="_blank">29328496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18633042">
<a name="18633042"></a>Schummer C, Wirsing M, Schummer W. The Pivotal Role of Vasopressin in Refractory Anaphylactic Shock. <i>Anesth Analg</i>. 2008;107(2):620-624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/18633042/pubmed" id="18633042" target="_blank">18633042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sperling.1">
<a name="Sperling.1"></a>Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11463411">
<a name="11463411"></a>Stiell IG, Hebert PC, Wells GA, et al. Vasopressin Versus Epinephrine for In hospital Cardiac Arrest: A Randomised Controlled Trial. <i>Lancet</i>. 2001;358(9276):105-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/11463411/pubmed" id="11463411" target="_blank">11463411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18254064">
<a name="18254064"></a>Traut U, Brügger L, Kunz R, et al. Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults. <i>Cochrane Database Syst Rev</i>. 2008;(1):CD004930. doi:10.1002/14651858.CD004930.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/18254064/pubmed" id="18254064" target="_blank">18254064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11373409">
<a name="11373409"></a>Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and Metabolic Effects of Low-Dose Vasopressin Infusions in Vasodilatory Septic Shock. <i>Crit Care Med</i>. 2001;29(3):487-493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/11373409/pubmed" id="11373409" target="_blank">11373409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3144593">
<a name="3144593"></a>Tuggle DW, Bennett KG, Scott J, Tunell WP. Intravenous vasopressin and gastrointestinal hemorrhage in children, <i>J Pediatr Surg</i>. 1988;23(7):627-629.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/3144593/pubmed" id="3144593" target="_blank">3144593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-UNOS.1">
<a name="UNOS.1"></a>UNOS. Critical Pathway for Donation After Cardiac Death. http://www.unos.org/docs/Critical_Pathway_DCD_Donor.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VanMatre.1">
<a name="VanMatre.1"></a>Van Matre E, Lyda C, Larkin M, McAlwee T, Wempe M, Kiser T. 970: Extended stability of vasopressin injection in polyvinyl chloride bags and syringes. <i>Crit Care Med</i>. 2019;47(1):463.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vasostrict.1">
<a name="Vasostrict.1"></a>Vasostrict (vasopressin) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14766695">
<a name="14766695"></a>Williams SR, Denault AY, Pellerin M, et al. Vasopressin for Treatment of Shock Following Aprotinin Administration. <i>Can J Anaesth</i>. 2004;51(2):169-172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/14766695/pubmed" id="14766695" target="_blank">14766695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15211159">
<a name="15211159"></a>Wise-Faberowski L, Soriano SG, Ferrari L, et al. Perioperative management of diabetes insipidus in children. <i>J Neurosurg Anesthesiol</i>. 2004;16(3):220-225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/15211159/pubmed" id="15211159" target="_blank">15211159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616207">
<a name="15616207"></a>Wood KE, Becker BN, McCartney JG, et al. Care of the Potential Organ Donor. <i>N Engl J Med</i>. 2004;351(26):2730-2739.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/15616207/pubmed" id="15616207" target="_blank">15616207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1447671">
<a name="1447671"></a>Wong AF, McCulloch LM, Sola A. Treatment of peripheral tissue ischemia with topical nitroglycerin ointment in neonates. <i>J Pediatr</i>. 1992;121(6):980-983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/1447671/pubmed" id="1447671" target="_blank">1447671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12176957">
<a name="12176957"></a>Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus Conference Report: Maximizing Use of Organs Recovered from the Cadaver Donor: Cardiac Recommendations: March 28-29, 2001, Crystal City, Va.<i>Circulation</i>. 2002;106(7):836-841.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/12176957/pubmed" id="12176957" target="_blank">12176957</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12876 Version 310.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
